Cargando…

Urinary-derived extracellular vesicles reveal a distinct microRNA signature associated with the development and progression of Fabry nephropathy

INTRODUCTION: Early initiation is essential for successful treatment of Fabry disease, but sensitive and noninvasive biomarkers of Fabry nephropathy are lacking. Urinary extracellular vesicles (uEVs) represent a promising source of biomarkers of kidney involvement. Among them, microRNAs (miRNAs) are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Levstek, Tina, Vujkovac, Bojan, Cokan Vujkovac, Andreja, Trebušak Podkrajšek, Katarina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076752/ https://www.ncbi.nlm.nih.gov/pubmed/37035314 http://dx.doi.org/10.3389/fmed.2023.1143905

Ejemplares similares

Biomarkers of Fabry Nephropathy: Review and Future Perspective
por: Levstek, Tina, et al.
Publicado: (2020)

Urinary Extracellular Vesicles and Their miRNA Cargo in Patients with Fabry Nephropathy
por: Levstek, Tina, et al.
Publicado: (2021)

Podocyturia in Fabry disease: a 10-year follow-up
por: Vujkovac, Bojan, et al.
Publicado: (2021)

Paricalcitol as an Antiproteinuric Agent Can Result in the Deterioration of Renal and Heart Function in a Patient with Fabry Disease
por: Keber, Tajda, et al.
Publicado: (2017)

Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors
por: Levstek, Tina, et al.
Publicado: (2023)

The Influence of Treatment with PCSK9 Inhibitors and Variants in the CRP (rs1800947), TNFA (rs1800629), and IL6 (rs1800795) Genes on the Corresponding Inflammatory Markers in Patients with Very High Lipoprotein(a) Levels
por: Levstek, Tina, et al.
Publicado: (2022)

Telomere Attrition in Chronic Kidney Diseases
por: Levstek, Tina, et al.
Publicado: (2023)

Telomere Attrition in Neurodegenerative Disorders
por: Levstek, Tina, et al.
Publicado: (2020)

Polymorphisms of the PPAR-γ (rs1801282) and Its Coactivator (rs8192673) Have a Minor Effect on Markers of Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus
por: Pleskovič, Aleš, et al.
Publicado: (2016)

Assessment of the Telomere Length and Its Effect on the Symptomatology of Parkinson’s Disease
por: Levstek, Tina, et al.
Publicado: (2021)

Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy
por: Warnock, David G, et al.
Publicado: (2015)

Vascular Endothelial Growth Factor Gene Polymorphism (rs2010963) and Its Receptor, Kinase Insert Domain-Containing Receptor Gene Polymorphism (rs2071559), and Markers of Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus
por: Merlo, Sebastjan, et al.
Publicado: (2016)

Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease
por: Cybulla, Markus, et al.
Publicado: (2022)

Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Polymorphism rs5498 of the ICAM-1 gene affects the progression of carotid atherosclerosis in patients with type 2 diabetes mellitus
por: Popović, Dražen, et al.
Publicado: (2016)

LPA Genotypes and Haplotypes Are Associated with Lipoprotein(a) Levels but Not Arterial Wall Properties in Stable Post-Coronary Event Patients with Very High Lipoprotein(a) Levels
por: Rehberger Likozar, Andreja, et al.
Publicado: (2021)

PECAM-1 gene polymorphism (rs668) and subclinical markers of carotid atherosclerosis in patients with type 2 diabetes mellitus
por: Popović, D, et al.
Publicado: (2016)

Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease
por: Goláň, Lubor, et al.
Publicado: (2015)

Special Issue “Genetics and Epigenetics in Endocrine Disorders”
por: Trebušak Podkrajšek, Katarina, et al.
Publicado: (2023)

Proteases and Protease Inhibitors of Urinary Extracellular Vesicles in Diabetic Nephropathy
por: Musante, Luca, et al.
Publicado: (2015)

Urinary Podocyte Loss Is Increased in Patients with Fabry Disease and Correlates with Clinical Severity of Fabry Nephropathy
por: Fall, Brent, et al.
Publicado: (2016)

Extracellular Vesicles Derived Human-miRNAs Modulate the Immune System in Type 1 Diabetes
por: Tesovnik, Tine, et al.
Publicado: (2020)

An Intron c.103-3T>C Variant of the AMELX Gene Causes Combined Hypomineralized and Hypoplastic Type of Amelogenesis Imperfecta: Case Series and Review of the Literature
por: Leban, Tina, et al.
Publicado: (2022)

Genome-wide Profiling of Urinary Extracellular Vesicle microRNAs Associated With Diabetic Nephropathy in Type 1 Diabetes
por: Ghai, Vikas, et al.
Publicado: (2017)

Urinary extracellular vesicles signature for diagnosis of kidney disease
por: Takizawa, Keiichi, et al.
Publicado: (2022)

Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation
por: Warnock, David G., et al.
Publicado: (2012)

Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study
por: Linhart, Aleš, et al.
Publicado: (2023)

Skeletal muscle releases extracellular vesicles with distinct protein and microRNA signatures that function in the muscle microenvironment
por: Watanabe, Sho, et al.
Publicado: (2022)

Cardiomyopathy and kidney function in agalsidase beta‐treated female Fabry patients: a pre‐treatment vs. post‐treatment analysis
por: Wanner, Christoph, et al.
Publicado: (2020)

Fabry nephropathy: a review – how can we optimize the management of Fabry nephropathy?
por: Waldek, Stephen, et al.
Publicado: (2014)

Correction to: Skeletal muscle releases extracellular vesicles with distinct protein and microRNA signatures that function in the muscle microenvironment
Publicado: (2023)

Discovering the Unexpected with the Utilization of NGS in Diagnostics of Non-syndromic Hearing Loss Disorders: The Family Case of ILDR1-Dependent Hearing Loss Disorder
por: Kovač, Jernej, et al.
Publicado: (2017)

A systematic review and Meta-analysis of urinary extracellular vesicles proteome in diabetic nephropathy
por: Ding, Xiaonan, et al.
Publicado: (2022)

Urinary Exosomal MicroRNA Signatures in Nephrotic, Biopsy-Proven Diabetic Nephropathy
por: Lee, Wen-Chin, et al.
Publicado: (2020)

Diabetic Nephropathy: Perspective on Extracellular Vesicles
por: Lu, Yanfang, et al.
Publicado: (2020)

The Importance of Early Genetic Diagnostics of Hearing Loss in Children
por: Božanić Urbančič, Nina, et al.
Publicado: (2020)

Novel GRHL2 Gene Variant Associated with Hearing Loss: A Case Report and Review of the Literature
por: Trebusak Podkrajsek, Katarina, et al.
Publicado: (2021)

Characterisation of adipocyte-derived extracellular vesicle subtypes identifies distinct protein and lipid signatures for large and small extracellular vesicles
por: Durcin, Maëva, et al.
Publicado: (2017)

MicroRNAs from extracellular vesicles as a signature for Parkinson's disease
por: Caldi Gomes, Lucas, et al.
Publicado: (2021)

Ciliary extracellular vesicles are distinct from the cytosolic extracellular vesicles
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_guogcghe83g4r7iev59iapebok